PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy
MWN-AI** Summary
PROCEPT BioRobotics (Nasdaq: PRCT) has announced the international launch of its HYDROS Robotic System, a cutting-edge platform designed to deliver Aquablation therapy for the treatment of benign prostatic hyperplasia (BPH). This system, which marks a significant advancement in robotic surgical technology, is the first to integrate artificial intelligence (AI) to enhance surgical precision through real-time ultrasound imaging and personalized treatment planning. This innovation aims to alleviate symptoms of BPH while preserving critical patient quality-of-life aspects such as sexual and urinary function.
The HYDROS system is particularly significant in expanding access to effective BPH treatments, addressing patient concerns regarding the side effects of long-term medication or invasive surgery. Larry Wood, President & CEO of PROCEPT BioRobotics, emphasized the system's role in providing clinically validated solutions that deliver durable symptom relief without compromising quality of life. The technology is particularly noted for its capability to combine surgeon judgment with robotic precision, thus facilitating tailored treatments that respect individual anatomy.
Neil Barber, a Consultant Urological Surgeon, praised the system for its ability to integrate AI capabilities into Aquablation therapy, which is already recommended by the National Institute for Health and Care Excellence (NICE) in the UK. The surgical community's acceptance of this innovative platform aligns with PROCEPT BioRobotics' objective to improve patient care through advanced solutions in urology.
With approximately 40 million men affected by BPH in the United States alone, the introduction of the HYDROS Robotic System represents a significant step forward. PROCEPT BioRobotics reinforces its commitment to advancing surgical standards and improving patient outcomes through its growing body of clinical evidence supporting Aquablation therapy.
MWN-AI** Analysis
PROCEPT BioRobotics (Nasdaq: PRCT) has recently announced the international launch of its HYDROS Robotic System, marking a significant milestone in the treatment landscape for benign prostatic hyperplasia (BPH). This AI-enabled platform represents an evolution in the application of Aquablation therapy, promising improved patient outcomes while expanding the company's global reach, particularly in regions like the UK.
Investors should take note of several key aspects driving this development. Firstly, the integration of AI in the HYDROS System enhances the precision and personalization of BPH treatments, addressing critical patient concerns about side effects associated with traditional surgical options. This could lead to increased adoption rates among both healthcare providers and patients who seek effective symptom relief with fewer trade-offs.
Furthermore, PROCEPT’s commitment to clinical validation is evidenced by its extensive repository of over 250 peer-reviewed publications, underscoring the efficacy and safety of Aquablation therapy. As the demand for minimally invasive and high-precision procedures grows, PROCEPT BioRobotics is well-positioned to capture market share in this expanding sector of urology.
Investors should also consider the broader context of the healthcare industry, particularly the rising prevalence of BPH among men. With approximately 40 million men affected in the U.S. alone, the market potential is substantial. The introduction of the HYDROS system not only enhances treatment options but also supports the healthcare system's shift towards personalized medicine.
In conclusion, PROCEPT BioRobotics offers a compelling investment opportunity fueled by innovation and clinical validation. Its strategic expansion into international markets with the HYDROS Robotic System enhances its growth potential, making it a stock worth monitoring for investors interested in the future of surgical robotics and urology solutions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT), today announced the international expansion of the HYDROS Robotic System, the company’s next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH).
HYDROS is the first AI-enabled robotic platform designed specifically for the treatment of BPH with Aquablation therapy. Leveraging AI-interpreted, real-time ultrasound imaging and advanced image-guided treatment planning, the system enables surgeons to deliver personalized, anatomy-specific therapy with robotic precision and reproducibility. The platform is designed to support scalable adoption across care settings while maintaining consistent procedural execution.
Aquablation therapy offers a complete solution for men living with BPH. A robust body of clinical evidence continues to demonstrate Aquablation delivers durable symptom relief while preserving sexual and urinary function, outcomes that are critically important to patients.
“Many men living with BPH remain on long-term medication or delay surgery because they are concerned about potential trade-offs between symptom relief and side effects,” said Larry Wood, President & CEO, PROCEPT BioRobotics. “The HYDROS Robotic System expands international access to a clinically validated, next-generation AI-enabled robotic solution that delivers durable symptom relief while preserving quality of life. We are proud to bring this innovation to physicians and patients across the UK and to continue expanding our international footprint.”
“The HYDROS Robotic System brings AI-enabled, real-time ultrasound-guidance and robotic assisted treatment planning to NICE-recommended Aquablation therapy in the UK, supporting precise, anatomy-specific treatment,” said Mr. Neil Barber, Consultant Urological Surgeon. “By combining surgeon judgement with robotic precision, Aquablation with HYDROS enables durable symptom relief and preservation of quality-of-life outcomes, including sexual and urinary function and meaningfully expands surgical choice for men living with BPH.”
Healthcare providers can learn more about the HYDROS Robotic System at: https://www.procept-biorobotics.com/healthcare-providers/hydros-robotic-system.
About Aquablation Therapy
Aquablation therapy is the first and only ultrasound guided, robotic-assisted, heat-free waterjet for the treatment of BPH. The system’s real-time ultrasound imaging provides the surgeon with a multi-dimensional view of the prostate enabling personalized treatment planning tailored to each patient’s unique anatomy. The surgeon can specify which areas of the prostate to remove while preserving the anatomy that controls erectile function, ejaculatory function and continence. Once the treatment plan is mapped by the surgeon, the predictable robotic-assisted execution enables prostate tissue to be removed in a precise, targeted and controlled fashion.
About PROCEPT BioRobotics® Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those anticipated or implied in such statements. PROCEPT BioRobotics undertakes no obligation to publicly update or revise any forward-looking statements.
Important Safety Information
All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/
Media Contact:
Matt Basco
Vice President, Investor Relations and Business Operations
PROCEPT BioRobotics
m.bacso@procept-biorobotics.com
FAQ**
How does the international expansion of the HYDROS Robotic System position PROCEPT BioRobotics Corporation PRCT in the competitive landscape of BPH treatment technologies?
What specific clinical evidence supports the effectiveness of Aquablation therapy as highlighted in PROCEPT BioRobotics Corporation PRCT's recent announcement?
In what ways might the AI-enabled features of the HYDROS Robotic System enhance procedural outcomes for surgeons using PROCEPT BioRobotics Corporation PRCT's technology?
How does PROCEPT BioRobotics Corporation PRCT plan to address potential market challenges in the adoption of Aquablation therapy in new international regions?
**MWN-AI FAQ is based on asking OpenAI questions about PROCEPT BioRobotics Corporation (NASDAQ: PRCT).
NASDAQ: PRCT
PRCT Trading
3.8% G/L:
$27.085 Last:
489,956 Volume:
$26.12 Open:
